GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for APOLLO

APOLLO

Official Title

A randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people

Overview

To provide new information regarding the role of aliskiren based BP lowering (with additional therapy with diuretics or CCB) in elderly individuals with SBP 130 to 159 mm Hg, in preventing major CV events and on global measures of physical, executive and cognitive function

Study Design

Randomized, multicenter, double 2X2 factorial design.

Primary Endpoint

the composite of CV death, non-fatal MI, non-fatal stroke, and significant heart failure; Secondary endpoints: Decline in the ability to perform everyday activities (key secondary outcome), renal dysfunction, and total mortality

Number of Patients

12500

Number of Sites

450

Number of Countries

30

Study Period

2010–2012

Principal Investigator

Koon Teo, Salim Yusuf

Program Manager

Jackie Bosch

Research Coordinator

Ingrid Copland